#Enoxaparin Sodium Injection Market value
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
130K people were victims of a chain letter scam that affected Tumblr in May 2011.
Text
Global Bovine Heparin Sodium Market [2024-2030] | Market Size, Growth, Dynamics and Trends
Global Info Research’s report offers key insights into the recent developments in the global Bovine Heparin Sodium market that would help strategic decisions. It also provides a complete analysis of the market size, share, and potential growth prospects. Additionally, an overview of recent major trends, technological advancements, and innovations within the market are also included.Our report further provides readers with comprehensive insights and actionable analysis on the market to help them make informed decisions. Furthermore, the research report includes qualitative and quantitative analysis of the market to facilitate a comprehensive market understanding.This Bovine Heparin Sodium research report will help market players to gain an edge over their competitors and expand their presence in the market.
According to our (Global Info Research) latest study, the global Bovine Heparin Sodium market size was valued at USD 41 million in 2023 and is forecast to a readjusted size of USD 60 million by 2030 with a CAGR of 5.6% during review period.
Bovine intestinal enoxaparin sodium and its injections can be used in anticoagulant, antithrombotic, anti-inflammatory, anticancer and halal drugs, that is, it has the halal property that porcine enoxaparin sodium does not have, and is widely used in Muslims, countries and countries. The region has a huge market. Global 5 largest manufacturers of Bovine Heparin Sodium are Bacto Chem, Syntex, Kin Master Produtos Químicos Ltda, Alliance Brasil and Ralington Pharma, which make up over 70%. Among them, Bacto Chem dominates with over 20% production value share, followed by Syntex (17%) and Kin Master Produtos Químicos Ltda (14%). Top manufacturers are based in South America, India and China.
Asia Pacific is the largest market, holding a share over 30%, followed by Europe and South America, with shares 30% and 20% separately.
Based on the product type, the Bovine Heparin Sodium is split into Type A and Type B.
Based on the product Application, the Bovine Heparin Sodium is primarily split into Treatment of Venous Thromboembolism, Cardioversion of Atrial Fibrillation/Flutter and Complications of Pregnancy. The largest segment is Treatment of Venous Thromboembolism, accounting for nearly 70%.
The Global Info Research report includes an overview of the development of the Bovine Heparin Sodium industry chain, the market status of Treatment of Venous Thromboembolism (Type A, Type B), Cardioversion of Atrial Fibrillation/Flutter (Type A, Type B), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Bovine Heparin Sodium.
Regionally, the report analyzes the Bovine Heparin Sodium markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Bovine Heparin Sodium market, with robust domestic demand, supportive policies, and a strong manufacturing base.
We have conducted an analysis of the following leading players/manufacturers in the Bovine Heparin Sodium industry: Kin Master Produtos Químicos Ltda、Syntex、Bacto Chem、Wegmed - Caminhos Medicinais Ltda、Alliance Brasil、Ralington Pharma、Hebei Changshan Biochemical Pharmaceutical、Suzhou Ronnsi Pharma Market segment by Type： Type A、Type B Market segment by Application：Treatment of Venous Thromboembolism、Cardioversion of Atrial Fibrillation/Flutter、Complications of Pregnancy、Others Report analysis: The Bovine Heparin Sodium report encompasses a diverse array of critical facets, comprising feasibility analysis, financial standing, merger and acquisition insights, detailed company profiles, and much more. It offers a comprehensive repository of data regarding marketing channels, raw material expenses, manufacturing facilities, and an exhaustive industry chain analysis. This treasure trove of information equips stakeholders with profound insights into the feasibility and fiscal sustainability of various facets within the market. Illuminates the strategic maneuvers executed by companies, elucidates their corporate profiles, and unravels the intricate dynamics of the industry value chain. In sum, the Bovine Heparin Sodium report delivers a comprehensive and holistic understanding of the markets multifaceted dynamics, empowering stakeholders with the knowledge they need to make informed decisions and navigate the market landscape effectively. Conducts a simultaneous analysis of production capacity, market value, product categories, and diverse applications within the Bovine Heparin Sodium market. It places a spotlight on prime regions while also performing a thorough examination of potential threats and opportunities, coupled with an all-encompassing SWOT analysis. This approach empowers stakeholders with insights into production capabilities, market worth, product diversity, and the markets application prospects. Assesses strengths, weaknesses, opportunities, and threats, offering stakeholders a comprehensive understanding of the Bovine Heparin Sodium markets landscape and the essential information needed to make well-informed decisions. Market Size Estimation & Method Of Prediction
Estimation of historical data based on secondary and primary data.
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Request Customization of Report@ https://www.globalinforesearch.com/contact-us About Us: Global Info Research is a company that digs deep into Global industry information to Bovine Heparin Sodium enterprises with market strategies and in-depth market development analysis reports. We provide market information consulting services in the Global region to Bovine Heparin Sodium enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
0 notes
Text
Enoxaparin Sodium Injection Market Value Report Forecast 2022-2030
Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country.
Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology
Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/enoxaparin-sodium-injection-market
Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.
This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
Market Segment Analysis:
Leading players of Enoxaparin Sodium Injection including:
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
The information for each competitor/Company Profile includes:
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Market split by Type, can be divided into:
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
Market split by Application, can be divided into:
Hospital
Clinic
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Market segment by Region/Country including:
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others
• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region.
• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.
• To profile key players and comprehensively analyze their market position in terms of core competencies.
• To analyze the markets situation with regard to industry trends, prospects, and contribution to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.
Key Indicators Analysed:
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase:
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/enoxaparin-sodium-injection-market
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research
#Enoxaparin Sodium Injection Market#Enoxaparin Sodium Injection#Enoxaparin Sodium Injection Market Sale#Enoxaparin Sodium Injection Market Share#Enoxaparin Sodium Injection Market Outlook#Enoxaparin Sodium Injection Market Value#Enoxaparin Sodium Injection Market Trend
0 notes
Text
Small Molecule Prefilled Syringes Market 2019 : Prime Challenges, Competitive Scenario
The global small molecule prefilled syringes market was valued at US$ 13,749.4 million in 2016 and is expected to witness a robust CAGR of 4.6% over the forecast period (2017–2025).
Manufacturers are focusing on capitalizing on patent losses to launch generic versions in the market. For instance, in 2017, Mylan N.V. launched generic alternative to Copaxone 40 mg/ml for multiple sclerosis patients in the U.S. Moreover, Mylan N.V. launched Brabio, first generic alternative to Copaxone 40 mg/ml, for multiple sclerosis patients in the U.K., in January 2018. Teva Pharmaceuticals enhanced presence in Multiple Sclerosis segment through the introduction of three-times-a-week Copaxone 40 mg/mL product in the U.S in 2014. In 2015, Teva Pharmaceuticals launched Generic Lovenox in the U.S. market. In 2016, Fresenius Kabi launched Ketorolac injection in its ready-to-administer prefilled glass syringe. Sandoz announced the U.S. Food & Drug Administration approval and launch of Glatopa (Glatiramer acetate) 40 mg/mL, in February 2018.
Key players in the market are focusing on collaborations, acquisitions, and partnerships, in order to enhance their market share. For instance, in 2013, Unilife Corporation entered into a long term supply contract with Sanofi S.A. The objective was to use Unilife’s Unifill Finesse platform of prefilled syringes with Sanofi S.A.’s Enoxaparin Sodium sold under brand names, Lovenox and Clexane. Pfizer, Inc. acquired Hospira, Inc. in the year 2015. Hospira, Inc. was a leading provider of injectable drugs and infusion technologies and this is expected to aid the company in increasing its market share. In 2016, Fresenius Kabi USA acquired BD Rx business from Becton, Dickinson, and Company. The business included pharmaceutical manufacturing plant and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes.
Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1629
Key Takeaways of the Small Molecule Prefilled Syringes Market:
The global small molecule prefilled syringes market is expected to exhibit a CAGR of 6% over the forecast period (2017–2025), owing to increasing product launches by manufacturers such as Mylan N.V., and Fresenius Kabi, AG in this prefilled syringes
Availability of small molecule therapies in neurology segment is very low and therefore, the segment has high growth potential
Major drugs in the neurology drugs segment such as Copaxone (manufactured by Teva Pharmaceutical Industries Ltd.) are expected to face competition from generics
Major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson, and Company, and Fresenius Kabi AG
However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.
Some major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, and Fresenius Kabi AG.
Click To Reading More On Small Molecule Prefilled Syringes Market
About Coherent Market Insights:
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]
https://www.coherentmarketinsights.com/phase-xs/
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 notes
Text
Prefilled Syringe Small Molecule Market:New Market Research Report Announced; Global Industry Analysis 2016 - 2024
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Snapshot
The prefilled syringes small molecule market was valued around US$ 12.03 Bn in 2015, accounting for significant market share of the global prefilled syringes market and anticipated to grow at substantial growth rate over the forecast period. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the prefilled syringe small molecule market in U.S. and EU-5 region over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in prefilled syringe small molecule market are presented in the report.
Download A PDF Sample Copy of Report: https://goo.gl/E6xfZD
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Drivers and Trends
U.S. and EU-5 market for prefilled syringe small molecule is expected to witness significant growth rate in terms of value owing to the technology innovations in pertaining to prefilled syringes, increasing demand for point of care administration, and change in patient behavior - seeking rapid relief through injectable drug delivery contributes to growth of the U.S. and EU-5 market for prefilled syringe small molecule. To understand and assess opportunities in this market, the report offers market forecast on the basis of therapeutic class and regions. The report provides analysis of the U.S. and EU-5 market for prefilled syringe small molecule in terms of market value (US$ Mn) and volume.
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Segmentation
Based on therapeutic class, the market is segmented into neurology drug, cardiovascular drugs, analgesics, adjuvants. The neurology drugs segment held a significant share of the U.S. and EU-5 prefilled syringes small molecule market. The segment is anticipated to witness high growth during the forecast period. The high growth of the segment is attributed to the popularity of non-availability of many generic equivalent drugs. This segment consists of the most prominent best-selling brand such as Copaxone. Moreover, recently launched neurological small molecule prefilled syringe such as the Glatopa by Sandoz, throw light upon the fact that neurology small molecule drug prefilled syringe are a strong strategic growth driver in the prefilled syringe small molecule space and are here to stay. Both in the U.S. and EU-5, the trend is upwards for neurological and cardiovascular small molecule prefilled syringe owing to the need of availability in emergency situations for self-medication and safe and accurate dose delivery.
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Geographical Outlook
Geographically, the prefilled syringe small molecule market is studied for U.S. and EU-5 region. In the U.S., a key trend in the market has been a rise of generic equivalent availabilities and market exclusivity agreements. Although the generic equivalent availability is comparatively better in the U.S. compared to EU-5, most key players operating in this market believe that further increasing foray of small molecules owing to patent expiry and generic equivalents availability is the key to grow prefilled syringe small molecule market.
The report includes a competitive landscape for prominent players in the prefilled syringe small molecule market. It has been included to provide a dashboard view of key companies operating in U.S. and EU-5 market for prefilled syringe small molecule. It also includes brief overview of prominent market strategies and SWOT analysis of the main players operational in the U.S. and EU-5 market for prefilled syringe small molecule.
Key Players Mentioned in this Report are:
Key players in the U.S. and EU-5 market for prefilled syringe small molecule are Teva Pharmaceutical Industries Ltd., Hospira, Inc (Now Pfizer, Inc.), Mylan N.V., Fresenius Kabi, Becton, Dickinson and Company and Sanofi.
Browse Global Strategic Business Report: https://goo.gl/pAJlnm
The U.S. and EU-5 market for prefilled syringe small molecule has been segmented as follows:
U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class
Neurology
Glatiramer Acetate
Cardiovascular Drugs
Atropine Sulfate
Furosemide
Verapamil Hydrochloride
Amiodarone
Epinephrine/Adrenaline
Enoxaparin sodium
Fondaparinux Sodium
Nadroparin Calcium
Dalteparin
Ephedrine
Analgesics
ketorolac Tromethamine
Morphine Sulphate
Dexamethasone Na Po4
Hydromorphone Hydrochloride
Adjuvants
Water for Injection
NaCl 0.9%/Saline
HPMC
Sodium Hyaluronate
25% Dextrose
Others
Diphenhydramine
Midazolam
Lidocaine Hydrochloride
Penicillin
Metoclopramide
Ondansetron
Methotrexate
Fibrin Sealant
Gadobutrol
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: www.transparencymarketresearch.com
0 notes
Text
** Enoxaparin Sodium Injection Market Size Report Forecast 2022-2030**
Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country.
Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology
Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/Enoxaparin-Sodium-Injection-Market
Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.
This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
Market Segment Analysis:
Leading players of Enoxaparin Sodium Injection including:
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
The information for each competitor/Company Profile includes:
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Market split by Type, can be divided into:
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
Market split by Application, can be divided into:
Hospital
Clinic
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Market segment by Region/Country including:
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others
• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region.
• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.
• To profile key players and comprehensively analyze their market position in terms of core competencies.
• To analyze the markets situation with regard to industry trends, prospects, and contribution to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.
Key Indicators Analysed:
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase:
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/Enoxaparin-Sodium-Injection-Market
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research/
#Enoxaparin Sodium Injection Market#Enoxaparin Sodium Injection#Enoxaparin Sodium Injection Market sale#Enoxaparin Sodium Injection Market price#Enoxaparin Sodium Injection Market value#Enoxaparin Sodium Injection Market share#Enoxaparin Sodium Injection Market outlook#Enoxaparin Sodium Injection Market trend#Enoxaparin Sodium Injection Market size
0 notes
Text
Enoxaparin Sodium Injection Market Share Report forecast 2022-2030
Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country.
Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology
Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/Enoxaparin-Sodium-Injection-Market
Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.
This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
Market Segment Analysis:
Leading players of Enoxaparin Sodium Injection including:
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
The information for each competitor/Company Profile includes:
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Market split by Type, can be divided into:
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
Market split by Application, can be divided into:
Hospital
Clinic
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Market segment by Region/Country including:
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others
• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region.
• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.
• To profile key players and comprehensively analyze their market position in terms of core competencies.
• To analyze the markets situation with regard to industry trends, prospects, and contribution to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.
Key Indicators Analysed:
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase:
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/Enoxaparin-Sodium-Injection-Market
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research/
#Enoxaparin Sodium Injection Market#Enoxaparin Sodium Injection#Enoxaparin Sodium Injection Market sale#Enoxaparin Sodium Injection Market price#Enoxaparin Sodium Injection Market value#Enoxaparin Sodium Injection Market share#Enoxaparin Sodium Injection Market outlook#Enoxaparin Sodium Injection Market trend
0 notes
Text
Enoxaparin Sodium Injection Market Global forecast 2022-2030
Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country.
Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology
Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/Enoxaparin-Sodium-Injection-Market
Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.
This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
Market Segment Analysis:
Leading players of Enoxaparin Sodium Injection including:
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
The information for each competitor/Company Profile includes:
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Market split by Type, can be divided into:
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
Market split by Application, can be divided into:
Hospital
Clinic
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Market segment by Region/Country including:
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others
• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region.
• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.
• To profile key players and comprehensively analyze their market position in terms of core competencies.
• To analyze the markets situation with regard to industry trends, prospects, and contribution to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.
Key Indicators Analysed:
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase:
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/Enoxaparin-Sodium-Injection-Market
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research/
#Enoxaparin Sodium Injection Market#Enoxaparin Sodium Injection#Enoxaparin Sodium Injection Market sale#Enoxaparin Sodium Injection Market price#Enoxaparin Sodium Injection Market value#Enoxaparin Sodium Injection Market share#Enoxaparin Sodium Injection Market outlook
0 notes
Text
**Enoxaparin Sodium Injection Market forecast 2022-2030**
Global Enoxaparin sodium market is estimated to be worth USD 2904.7 Million in 2020 and is projected to grow at a CAGR of 8.20% between 2017 to 2028. The study has considered the base year as 2020, which estimates the market size of market and the forecast period is 2021 to 2028. The report analyzes and forecasts the market size, in terms of value (USD Million), for the market. The report segments the market and forecasts its size, by drugs type, by application, by sales channels and region/country.
Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology
Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/4/Enoxaparin-Sodium-Injection-Market
Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth. Rise in awareness for the treatment of several cardiovascular disease fuels the market growth. In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
The enoxaparin sodium market size is expected to be valued at USD 5334.8 million by 2028. The enoxaparin sodium market is segmented into type, application, and sales channel. Based on the type, enoxaparin sodium market is segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, and others. Based on the application, enoxaparin sodium market is segmented into hospitals, clinics, and others. Based on the sales channel, enoxaparin sodium market is bifurcated into direct channel and indirect channel.
This report provides detailed historical analysis of global market for Enoxaparin Sodium Injection from 2016-2021, and provides extensive market forecasts from 2022-2030 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Enoxaparin Sodium Injection market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries. Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends. In the end, this report also provides in-depth analysis and professional advices on how to face the post COIVD-19 period.
Market Segment Analysis:
Leading players of Enoxaparin Sodium Injection including:
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
The information for each competitor/Company Profile includes:
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Market split by Type, can be divided into:
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
Market split by Application, can be divided into:
Hospital
Clinic
Others
Market split by Sales Channel, can be divided into:
Direct Channel
Distribution Channel
Enoxaparin is commonly used in cardiac patients. As with all low molecular weight heparins, (LMWHs) the drug is easy to administer subcutaneously as compared with intravenous infusion of unfractionated heparin. Unlike other LMWHs, enoxaparin has been shown to be superior to intravenous unfractionated heparin in patients with non-ST elevation and ST elevation acute coronary syndromes (ACS), and a comparable agent in patients undergoing elective percutaneous coronary intervention (PCI) with decreased bleeding. However, elective PCI in patients without ACS is currently not in the enoxaparin label. It primarily inhibits factors Xa and IIa with a greater effect on factor Xa. Enoxaparin is renally cleared and a dose adjustment by 50% reduction is recommended for patients with creatinine clearance below 30 ml/min. In patients aged 75 years or older undergoing fibrinolysis, it is recommended that the intravenous bolus of 30 mg be omitted and that only 75% of the usually recommended dose of 1 mg/kg subcutaneously twice-daily be administered.
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Market segment by Region/Country including:
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa. In 2020, Europe is anticipated to dominate the Enoxaparin sodium market with a market revenue of 1,224.32 USD Million with a registered CAGR of 8.53%.
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Spain etc.)
Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
South America (Brazil, Argentina and Colombia etc.)
Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)
The scope of the Enoxaparin sodium market report includes a detailed study of Enoxaparin sodium and regional markets for Enoxaparin sodium industry. The Enoxaparin sodium market report is segmented by product type, by application and by region. It reveals market situation and future forecast. The study also covers the significant data presented with the help of graphs and tables. The Enoxaparin sodium market report covers information regarding competitive outlook including the company profiles of the key participants operating in the Enoxaparin sodium market. Key players profiled in the report include Sanodz, Winthrop U.S., Sanofi, Themis Medicare Limited, Actavis Pharma Company, Shenzhen Techdow Pharmaceutical and Others
• To define and describe the Enoxaparin sodium market segmented by drug type, by application, by sales channel and by geographic region.
• To estimate and forecast the market size for various segments with regard to regions: North America, Europe, Asia Pacific, South America and Middle East and Africa.
• To profile key players and comprehensively analyze their market position in terms of core competencies.
• To analyze the markets situation with regard to industry trends, prospects, and contribution to the total market by identifying the high-growth segments of the Enoxaparin sodium market and provide the competitive landscape.
Key Indicators Analysed:
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2030 & Sales with a thorough analysis of the markets competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase:
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/4/Enoxaparin-Sodium-Injection-Market
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/intel-market-research/
#Enoxaparin Sodium Injection Market#Enoxaparin Sodium Injection#Enoxaparin Sodium Injection Market sale#Enoxaparin Sodium Injection Market price#Enoxaparin Sodium Injection Market value#Enoxaparin Sodium Injection Market outlook
0 notes
Text
U.S. And EU-5 Prefilled Syringe Small Molecule Market: Emerging Trends & Forecast 2016 - 2024
The top three players operating in the U.S. and EU-5 prefilled syringe small molecule market raked in a share of 70% in the overall market in 2015, observes Transparency Market Research. The players, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sanofi, have held a dominant position in the overall market for a significant period of time. Teva’s lion’s share is attributable to its popular drug brand known as Copaxone. These players have been thriving on intensive investment on research and development and product innovation. “Several pharmaceutical companies are focusing on developing large molecules development and significant product pipelines to gain a competitive edge,” states the lead author of this research report.
According to the research report, the U.S. and EU-5 prefilled syringe small molecule market is expected to be worth US$17.1 bn by the end of 2024 as against US$9.15 bn in 2015. Analysts anticipate that the market will progress between the CAGR of 6.0 % to 8.0 % during the forecast period of 2016 and 2024.
Neurology Drugs to Remain in High Demand throughout Forecast Period
The neurology segment is the dominant segment in the overall market and is expected to lead the market with soaring sales of its popular drug brand Copaxone for treating multiple sclerosis (MS). By the end of 2024, the neurology drugs segment is expected to make a sale of 40.3 million units. In terms of regions, the U.S. is projected to acquire a share of 68.3% by the end of 2024.
Technological Innovations keep Momentum Steady in Overall Market
The U.S. and EU-5 prefilled syringe small molecule market is estimated to grow at a rapid pace in the coming few years due to incredible technological innovations. These innovations have brought in new materials and device functions for prefilled syringes. For instance, BD plans to launch COP (Cyclo-olefin-polymer) syringes that will be used for biopharmaceuticals. The biggest benefit of these syringes is that they have exceptionally low silicone, super low tungsten, and very low particles value. Manufacturers are also designing plastic syringes with COPs that have the advantage of ultra-high purity polymer with low off-gas and leachable content as compared to glass syringes.
Analysts predict that the demand for prefilled syringes will exhibit continued growth as they offer injectable drug delivery that can be easily performed at home. Thus, prefilled syringes have completely eliminated the need for hospitals and trained medical staff, thereby reducing the cost of healthcare for the patients. The ability to see the vials has also prompted the usage of prefilled syringes for managing diseases such as diabetes, rheumatoid arthritis, and kidney diseases.
Product Recalls Shadow Positive Perception and Hamper Market Growth
The shift in preference for large molecules biologics is estimated to restrain the demand for prefilled syringes for small molecules in the coming years. The market is also likely to be restrained by the growing concerns pertaining to the product quality and inaccuracy of dosage. These factors have also led to product recalls in the recent past. Against this background, several healthcare professionals are using other formulations of the same drug to treat the patients.
This review is based on Transparency Market Research’s report, titled “Prefilled Syringe Small Molecule Market – U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class
Neurology
Glatiramer Acetate
Cardiovascular Drugs
Atropine Sulfate
Furosemide
Verapamil Hydrochloride
Amiodarone
Epinephrine/Adrenaline
Enoxaparin sodium
Fondaparinux Sodium
Nadroparin Calcium
Dalteparin
Ephedrine
Analgesics
ketorolac Tromethamine
Morphine Sulphate
Dexamethasone Na Po4
Hydromorphone Hydrochloride
Adjuvants
Water for Injection
NaCl 0.9%/Saline
HPMC
Sodium Hyaluronate
25% Dextrose
Others
Diphenhydramine
Midazolam
Lidocaine Hydrochloride
Penicillin
Metoclopramide
Ondansetron
Methotrexate
Fibrin Sealant
Gadobutrol
Download Free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16988
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com
0 notes
Text
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Ease of Operation in Disease Management Helps Sustain Growth, observes TMR
The top three players operating in the U.S. and EU-5 prefilled syringe small molecule market raked in a share of 70% in the overall market in 2015, observes Transparency Market Research. The players, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sanofi, have held a dominant position in the overall market for a significant period of time. Teva’s lion’s share is attributable to its popular drug brand known as Copaxone. These players have been thriving on intensive investment on research and development and product innovation. “Several pharmaceutical companies are focusing on developing large molecules development and significant product pipelines to gain a competitive edge,” states the lead author of this research report.
According to the research report, the U.S. and EU-5 prefilled syringe small molecule market is expected to be worth US$17.1 bn by the end of 2024 as against US$9.15 bn in 2015. Analysts anticipate that the market will progress between the CAGR of 6.0 % to 8.0 % during the forecast period of 2016 and 2024.
Neurology Drugs to Remain in High Demand throughout Forecast Period
The neurology segment is the dominant segment in the overall market and is expected to lead the market with soaring sales of its popular drug brand Copaxone for treating multiple sclerosis (MS). By the end of 2024, the neurology drugs segment is expected to make a sale of 40.3 million units. In terms of regions, the U.S. is projected to acquire a share of 68.3% by the end of 2024.
Technological Innovations keep Momentum Steady in Overall Market
The U.S. and EU-5 prefilled syringe small molecule market is estimated to grow at a rapid pace in the coming few years due to incredible technological innovations. These innovations have brought in new materials and device functions for prefilled syringes. For instance, BD plans to launch COP (Cyclo-olefin-polymer) syringes that will be used for biopharmaceuticals. The biggest benefit of these syringes is that they have exceptionally low silicone, super low tungsten, and very low particles value. Manufacturers are also designing plastic syringes with COPs that have the advantage of ultra-high purity polymer with low off-gas and leachable content as compared to glass syringes.
Analysts predict that the demand for prefilled syringes will exhibit continued growth as they offer injectable drug delivery that can be easily performed at home. Thus, prefilled syringes have completely eliminated the need for hospitals and trained medical staff, thereby reducing the cost of healthcare for the patients. The ability to see the vials has also prompted the usage of prefilled syringes for managing diseases such as diabetes, rheumatoid arthritis, and kidney diseases.
Product Recalls Shadow Positive Perception and Hamper Market Growth
The shift in preference for large molecules biologics is estimated to restrain the demand for prefilled syringes for small molecules in the coming years. The market is also likely to be restrained by the growing concerns pertaining to the product quality and inaccuracy of dosage. These factors have also led to product recalls in the recent past. Against this background, several healthcare professionals are using other formulations of the same drug to treat the patients.
This review is based on Transparency Market Research’s report, titled “Prefilled Syringe Small Molecule Market - U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class
Neurology
Glatiramer Acetate
Cardiovascular Drugs
Atropine Sulfate
Furosemide
Verapamil Hydrochloride
Amiodarone
Epinephrine/Adrenaline
Enoxaparin sodium
Fondaparinux Sodium
Nadroparin Calcium
Dalteparin
Ephedrine
Analgesics
ketorolac Tromethamine
Morphine Sulphate
Dexamethasone Na Po4
Hydromorphone Hydrochloride
Adjuvants
Water for Injection
NaCl 0.9%/Saline
HPMC
Sodium Hyaluronate
25% Dextrose
Others
Diphenhydramine
Midazolam
Lidocaine Hydrochloride
Penicillin
Metoclopramide
Ondansetron
Methotrexate
Fibrin Sealant
Gadobutrol
Download Free exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16988
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com
0 notes